

Focal Points: Hormonal Treatment for Breast Cancer | Focus On Practice Management Systems | CancerNetwork Podcasts

[Register](#)

Oncology NEWS Today | CME | E-Learning | E-Textbooks | Podcasts | Supplements | Conference Reports | Meetings & Courses | Classifieds | Subscribe | Contact Us
Breast Cancer | Colorectal Cancer | Lung Cancer | Nausea & Vomiting | Ovarian Cancer | Prostate Cancer | Skin Cancer | More Topics



Search

Powered by SearchMedica

SearchMedica recommended medical sites Search CancerNetwork Prioritize Results by Publication Date

FREE Physician-only E/M Audio Conference **\$199 Value**
Complete a short survey to register.

February 25, 2009
Oncology News International. Vol. 18 No. 2
NEWS & ANALYSIS

New outlook for neuroendocrine cancer

CAROLINE HELWICK

SAN FRANCISCO—Two agents dramatically delayed the time to disease progression in metastatic neuroendocrine tumors, according to reports at the 2009 Gastrointestinal Cancers Symposium.

The PROMID study (Placebo-controlled prospective Randomized study on the antiproliferative efficacy of Octreotide LAR in patients with metastatic neuroendocrine MIDgut tumors) evaluated the antitumor effects of the somatostatin analog octreotide acetate (Sandostatin LAR), which already is used to treat the severe diarrhea and flushing associated with neuroendocrine tumors (NET).

"This study demonstrates that octreotide also helps control tumor growth," said Rudolf Arnold, MD, of Philipps-University Marburg in Germany, who added that the mechanism for its antitumor effects is unclear. "Currently, the only effective therapy for NET is surgery; however, many malignant tumors are metastatic. New regimens with few or minimal side effects, therefore, are highly desired."

The multicenter prospective phase III trial, conducted in Germany, randomized 85 patients with metastatic NET of the midgut to receive first-line treatment with 30 mg of octreotide LAR or placebo every four weeks for 18 months or until tumor progression (abstract 121).

Octreotide LAR reduced the risk of progression of disease by 66%, producing a median time to progression (TTP) of 14.3 months, compared with six months in the placebo arm ($P = .000072$), Dr. Arnold reported.

For most patients, stable disease was the best response and this was observed in 64% with octreotide and 37% with placebo ($P = .0079$). One patient per arm had a partial response. The drug worked in patients with both functioning and nonfunctioning tumors.

Low hepatic burden

The most favorable effect was observed among the 70% of patients with a low hepatic tumor load ($\leq 10\%$ ($P < .0009$)) and in patients with a resected primary tumor ($P < .01$). In patients with low hepatic load, the time-to-progression was 27.14 months with octreotide, compared with 7.21 months with placebo, for a reduction in risk of 74%. Patients with higher hepatic tumor loads had a nonsignificant 36% reduction in risk and a TTP of 10.35 months vs 5.45 months.

While the overall survival estimate is premature, median survival was 73.7 months in the placebo arm but has not been reached in the octreotide arm after 77 months. Octreotide was well tolerated, with no difference in serious adverse events between the arms (abstract 122).



**"Durable responses...
were observed among
patients with chemo-
therapy refractory
pancreatic NET."**

—JAMES YAO, MD

At a symposium press conference, Jennifer Obel, MD, a gastrointestinal oncologist at NorthShore Health Systems in

Article Tools

- Send as email
- Print this page
- Discuss this article on Peerclip

Cancer Management

Don't miss the 10th edition of **Cancer Management: A Multidisciplinary Approach**. Brought to you by the publishers of the journal Oncology. [Read more>>](#)

The landscape has changed.

GEMZAR/carboplatin for
the 2nd-line treatment of
advanced ovarian cancer.

Stay aware. Sign up for email updates today.

Visit GEMZAR.com

GEMZAR
gemcitabine HCl
(for injection)

It takes a team.

Important Safety Information

GEMZAR in combination with carboplatin is indicated for the treatment of patients with advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.

Chicago, commended the researchers for incorporating a control group.


"This allows us to evaluate whether this tumor's slow growth is due to biology or is affected by the treatment," Dr. Obel said. "I think this study demonstrates that delay of progression was related to the medication. These findings are practice-changing."

mTOR inhibitor

Other investigators reported that the mTOR inhibitor everolimus (RAD001) may also be beneficial for pancreatic NET. The phase II trial included 160 patients with metastatic disease who had progressed after chemotherapy and were treated with 10 mg of everolimus or everolimus plus octreotide. Most patients responded or achieved stable disease.

Clinical benefit was observed by central review in 76.5% with everolimus monotherapy and in 82.2% with everolimus plus octreotide, and by investigator assessment in 73% and 80%, respectively.

Median response duration with the single agent was 10.8 months by central review and 10.15 months by investigator assessment, but it has not been reached for the combination. Progression-free and overall survival rates were higher with the combination (see Figure on pages 1 and 4).



Approximately half the patients with abnormal baseline levels of the circulating neuroendocrine marker chromogranin achieved significant reductions or normalization of levels with treatment.

Their TTP was significantly longer than that of patients whose levels were not affected.

"Durable responses and stable disease were observed among patients with chemotherapy- refractory pancreatic NET.

The progression-free and overall survival data support the efficacy of RAD001," said lead author James Yao, MD, of M.D. Anderson Cancer Center in Houston. The symposium was jointly sponsored by ASCO, the American Society for Radiation Oncology, the Society for Surgical Oncology, and the American Gastroenterological Association.

What Your Colleagues Are Reading...

[Rising PSA in Nonmetastatic Prostate Cancer](#)
Oncology, November 1, 2007

[Cancer Management: A Multidisciplinary Approach](#)
Oncology, June 1, 2007

[More proton therapy centers on the horizon](#)
Oncology News International, April 1, 2008

[Primary and metastatic brain tumors](#)
Cancer Management: A Multidisciplinary Approach, 10th Edition (2007), June 1, 2007

[Head and Neck Tumors](#)
Cancer Management: A Multidisciplinary Approach, 10th Edition (2007), June 1, 2007

What's New in Oncology/Hematology

[Consortium advances multidisciplinary program for colon cancer](#)
Oncology News International, February 25, 2009

[NSABP B-30: Amenorrhea relates to survival](#)
Oncology News International, February 25, 2009

[Multidisciplinary approach improves rectal cancer outcomes](#)
Oncology News International, February 25, 2009

[Cancer luminary lambasts slow-moving U.S. clinical trials](#)
Oncology News International, February 25, 2009

[Improvements in Pap screenings proposed](#)
Oncology News International, February 25, 2009

[Trastuzumab in the adjuvant setting: Is concurrent treatment better than sequential?](#)
Oncology News International, February 25, 2009

[Varian places RT units; offers storage system](#)
Oncology News International, February 25, 2009

[Radiation oncology society adopts new moniker](#)
Oncology News International, February 25, 2009

[Growth of Medicare HMOs could impact clinical trials](#)
Oncology News International, February 25, 2009

[Easy methods curtail toxins in food linked to cancer in Africa](#)
Oncology News International, February 25, 2009



CLICK HERE TO DOWNLOAD AND SHARE THIS INFORMATIVE
PODCAST WITH YOUR PATIENTS

**Addressing an Unmet Need for
Patients With Advanced Breast Cancer**

 
In collaboration with Bristol-Myers Squibb

[CancerNetwork](#) | [ConsultantLive](#) | [Diagnostic Imaging](#) | [Psychiatric Times](#) | [Physicians Practice](#) | [SearchMedica](#)



CMPMedica

© 1996 - 2009 CMPMedica LLC, a United Business Media company
[Privacy Statement](#) - [Your California Privacy rights](#) - [Terms of Service](#)

Additional online resources from CMPMedica

Professional medical search at [SearchMedica](#)
Medical imaging news and features at [Diagnostic Imaging](#)
Clinical psychiatric news and special reports at [Psychiatric Times](#)
Cancer diagnosis, treatment, and prevention at [Cancer Network](#)
Practice management resources at [Physicians Practice](#)
[CT Dose Issues and Articles](#)

Practical clinical advice at [Consultant Live](#)
Continuing medical educational at [CME LLC](#)
[Medical Imaging and Radiology White Papers](#)
[Podcasts for Oncologists](#)
[Medical Search Tips Newsletter](#)
[Consumer Healthcare Information](#)